Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Becareful

<< Previous

Bullboard Posts

Next >>

Comment by Northstar49on Nov 17, 2020 8:31pm

227 Views

Post# 31919636

RE:Becareful

100% of the time.

After a reverse split, if the company is worth the evaluation then it will hold at that price.

If not "see you back at 0.40"

Q: Why has the stock price not moved up or down? Answer that question and you will understand.

Stay Thirsty........

<< Previous

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (Nov. 8, 2024)